Drugs / Viral Specific T-cells
Viral Specific T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04230356 | Jan 2021 → Mar 2028 expected | disease related to hematopoietic stem cell transplant, viral infectious disease | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 2 | NCT04331275 | Aug 2020 → Sep 2026 overdue | disease related to solid organ transplantation, viral infectious disease | Children's Hospital Medical Center, Cincinnati | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Viral Specific T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04230356 ↗ |
| Known as | viral specific T-lymphocytes | “viral specific T-lymphocytes (VSTs) to prevent or treat viral infections” NCT04230356 ↗ |
| Known as | VSTs | “VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT).” NCT04230356 ↗1“Viral Specific T-cells (VSTs)” NCT04331275 ↗ |
| Modality | Cell therapy | “VSTs are cells specially designed to fight viral infections that may happen after a stem cell transplant (SCT).” NCT04230356 ↗ |
| Route | Intravenous | “VSTs are given through an IV infusion 21-30 days after transplant” NCT04230356 ↗ |